Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study.

Abstract

135 patients were entered into a 28-day randomized double-masked multicentre study comparing the efficacy and short-term safety of lodoxamide 0.1% ophthalmic solution (Alomide--Alcon Laboratories), a mast cell stabilizer, with sodium cromoglycate 2% ophthalmic solution (Opticrom--Fisons Pharmaceuticals) in the treatment of allergic eye disease. Patients given lodoxamide 0.1% showed a significantly more rapid and greater improvement in their signs and symptoms of allergic eye disease than patients given sodium cromoglycate 2%. Both treatments were found to be safe, and side-effect profiles were comparable between the two treatment groups, although the overall incidence of side-effects in this study was found to be less frequent in the lodoxamide-treated group.

• Authors: G T Fahy, D L Easty, L M Collum, A Benedict-Smith, M Hillery, D G Parsons
• Journal: European journal of ophthalmology (Eur J Ophthalmol) 1992 Jul-Sep Vol. 2 Issue 3 Pg. 144-9 ISSN: 1120-6721 [Print] United States
• PMID: 1450659 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Ophthalmic Solutions
• Cromolyn Sodium
• Oxamic Acid
• lodoxamide ethyl

Topics

• Adolescent
• Adult
• Aged
• Child
• Child, Preschool
• Conjunctivitis, Allergic (drug therapy)
• Cromolyn Sodium (adverse effects, therapeutic use)
• Double-Blind Method
• Drug Tolerance
• Female
• Humans
• Male
• Middle Aged
• Ophthalmic Solutions (therapeutic use)
• Oxamic Acid (administration & dosage, analogs & derivatives, therapeutic use)